ETOPOPHOS® (etoposide phosphate) for Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.
ETOPOPHOS (etoposide phosphate) for Injection is an antineoplastic agent which is available for intravenous infusion as a sterile lyophile in single-dose vials containing etoposide phosphate equivalent to 100 mg etoposide, 32.7 mg sodium citrate USP, and 300 mg dextran 40. Etoposide phosphate is a water soluble ester of etoposide (commonly known as VP-16), a semi-synthetic derivative of podophyllotoxin. The water solubility of etoposide phosphate lessens the potential for precipitation following dilution and during intravenous administration.
ETOPOPHOS for Injection is indicated in the management of the following neoplasms:
Refractory Testicular Tumors- ETOPOPHOS for Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy.
Small Cell Lung Cancer- ETOPOPHOS for Injection in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.
Media Articles Related to Etopophos (Etoposide)
Effects of chemotherapy on developing ovaries in female fetuses
Source: Cancer / Oncology News From Medical News Today [2016.08.11]
The chemotherapy drug etoposide may have adverse effects on the developing ovaries of female fetuses, according to a study in mouse cells published in the open access journal BMC Cancer.
Published Studies Related to Etopophos (Etoposide)
Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. [2011.08.27]
In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology.To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). [2011.05]
CONCLUSION: This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. [2011.03]
PURPOSE: A randomized clinical trial examined whether dexamethasone administration prior to ondansetron followed by etoposide and carboplatin infusions, and single-nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify etoposide pharmacokinetics in pediatric patients... CONCLUSION: Pharmacokinetics of etoposide was influenced by BW on an allometric basis in this pediatric population. Dexamethasone did not influence etoposide pharmacokinetics during these 3-5 days courses. These results should allow a better individualization of etoposide dosing in children.
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. [2011.01]
Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), is used in cancer patients as a supportive care for anemia. For small-cell lung cancer (SCLC), several studies have shown that the administration of ESAs does not affect survival but decreases the need for blood transfusions and improves the quality of life (QOL) of patients receiving chemotherapy...
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. [2010.12.01]
CONCLUSIONS: The overall rate of Grade 2 to 5 RP was 7% in patients treated with chemoradiotherapy. In this analysis, predictive factors for RP were MLD > 18 Gy and treatment with CD. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Clinical Trials Related to Etopophos (Etoposide)
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas [Completed]
Primary Objective: To determine maximum tolerated dose & dose limiting toxicity of
vandetanib when combined with standard dosing of etoposide among patients with recurrent
malignant glioma who are on & not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary
Objectives: To assess safety & tolerability of vandetanib + etoposide in this population; To
evaluate pharmacokinetics of vandetanib among malignant glioma patients on & not on EIAEDs
when combined with etoposide.
Exploratory Objective: To evaluate for evidence of anti-tumor activity of study regimen
among recurrent malignant glioma patients including radiographic response rate, 6-month
progression free survival (PFS) rate & median PFS.
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG [Completed]
Primary Objective to estimate 6-month progression free survival probability of patients with
recurrent malignant glioma treated with Etoposide + Bevacizumab.
Secondary Objectives To evaluate safety & tolerability of Etoposide + Bevacizumab among
patients with recurrent malignant glioma (RMG).
To evaluate radiographic response, progression free survival & overall survival of patients
with recurrent malignant glioma treated with Etoposide + Bevacizumab.
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan [Completed]
Primary objective To estimate 6-month progression free survival probability of pts w
recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on
bev + irinotecan Secondary Objectives To evaluate safety & tolerability of bev + either
daily temozolomide/etoposide among pts w recurrent GBM who have progressed on bev +
irinotecan To evaluate radiographic response, progression free survival & overall survival
of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following
progression on bev + irinotecan
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma [Completed]
High-risk neuroblastoma is an aggressive childhood cancer that shows up as a lump or mass in
the belly or around the spinal cord in the chest, neck, or pelvis. Often the tumor has
spread around the body to the bones or to the soft center of the bone, called the bone
marrow. High-risk neuroblastoma often responds to treatment at first, but it frequently
comes back and may be even more difficult to treat.
Chemotherapy (drug treatments for cancer) is usually given at high doses in short bursts (3
to 5 days) followed by a few weeks of rest and recovery. This burst and recovery is called a
"cycle" and usually takes about 21 days. Some scientists and physicians have tried to give
chemotherapy at lower doses for more days, called "metronomic" chemotherapy. This method of
giving chemotherapy has been used to treat neuroblastoma that has failed more standard types
of treatment (relapsed neuroblastoma) and has shown some promise for those patients. One of
the reasons it may work is by killing the blood vessels that feed the tumor as well as
killing tumor cells themselves (the way that burst chemotherapy works). We think that giving
a burst of chemotherapy together with metronomic therapy may kill the tumor while decreasing
the side effects that we have seen in the past.
Treatment for high risk neuroblastoma usually occurs in 3 stages: induction, consolidation,
and maintenance. During the induction phase, patients will receive chemotherapy and possibly
more surgery to get rid of most of the tumor cells. Most of the chemotherapy drugs during
induction will be given in the standard burst method. One of the chemotherapy drugs,
etoposide, will be given in lower, metronomic doses. The doctors will study how the tumors
respond and the side effects patients have. After induction most childrens' tumors will have
disappeared, also called remission. These children will receive the second stage of
treatment called consolidation. During this stage, subjects will receive radiation
treatments to the tumor and then higher doses of chemotherapy. Because of the side effects
of the high doses of chemotherapy, we will collect and store some special blood cells
(called hematopoietic stem cells) early in treatment and keep them frozen. After the high
doses of chemotherapy, these cells will be thawed and given to the subject. . This is called
hematopoietic stem cell transplant (HSCT). The final stage of treatment, called maintenance,
consists of a drug taken by mouth for 6 months.
Surgery to remove large, or bulky, tumors is a standard part of treatment for high risk
neuroblastoma. A few children can have their main tumor removed before chemotherapy, but
most require the tumor to shrink first. Surgery has usually been scheduled for after 3 to 5
cycles of therapy, but no one really knows how quickly the tumors are ready to come out.
Because chemotherapy has significant side effects that can change the risks of surgery, we
will study how early surgeries to remove tumors can happen.
This study is being done to evaluate the outcomes of disease response and survival in
children with high risk neuroblastoma treated on this regimen.
Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas [Recruiting]
The Phase I part of the study will apply to identify dose-limiting toxicities (DLT) and to
define maximum-tolerated dose (MTD) for a new chemoimmunotherapy combination of
bendamustine, ofatumumab, carboplatin, and etoposide in patients with Non Hodgkin's lymphoma
whose disease has progressed or has recurred after prior chemotherapy.
The Phase II part of the study will be a single-arm, open-label study in which all patients
will receive combination bendamustine, ofatumumab, carboplatin and etoposide at the MTD dose
defined in phase I.
This study hopes to identify a life-prolonging therapy for patients with Non-Hodgkin's
Lymphoma whose disease has progressed or has recurred after prior chemotherapy. The
hypothesis is that the proposed combination of chemotherapy is well-tolerated and is
efficacious for the treatment of relapsed/refractory aggressive B cell lymphomas.
Page last updated: 2016-08-11